Bone Biologics

Bone Biologics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bone Biologics (BBLG) as of Oct 18, 2026 is -3.23 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -4.22 M USD — a change of -23.32% (higher).

EBITDA

-3.23 MUSD

YoY

-23.32%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bone Biologics is 2025 -3.23 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bone Biologics was 2024 -4.22 M USD. It decreases by -23.32% higher compared to the previous year.

The Bone Biologics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-2.79 M USD
Jan 1, 2019
-2.45 M USD
Jan 1, 2020
-825,014.00 USD
Jan 1, 2021
-1.10 M USD
Jan 1, 2022
-3.67 M USD
Jan 1, 2023
-9.43 M USD
Jan 1, 2024
-4.22 M USD
Jan 1, 2025
-3.23 M USD
The Bone Biologics EBITDA history
YEAREBITDAYoY
-3.23 MUSD-23.32%
-4.22 MUSD-55.25%
-9.43 MUSD+157.23%
-3.67 MUSD+232.75%
-1.10 MUSD+33.51%
-825,014.00USD-66.29%
-2.45 MUSD-12.31%
-2.79 MUSD+6.26%
-2.63 MUSD-85.29%
-17.85 MUSD+48.83%
-12.00 MUSD+298.41%
-3.01 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bone Biologics Stock analysis

What does Bone Biologics do? Bone Biologics Corp, headquartered in Burlington, Massachusetts, is a biotechnology company focused on bone regeneration for spinal fusion procedures. The company, listed on 27 November 2015, employs two full-time staff and develops the NELL-1 protein, a recombinant human skeletal growth factor. NELL-1 combines with demineralized bone matrix (DBM) to create the NELL-1/DBM Fusion Device, targeting spine implants, non-union trauma cases, and osteoporosis treatment. The technology is designed to provide precise control over bone and cartilage regeneration through laboratory and animal research applications. Bone Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bone Biologics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bone Biologics is -3.23 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bone Biologics changed from -4.22 M USD to -3.23 M USD, representing a -23.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Bone Biologics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Bone Biologics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Bone Biologics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Bone Biologics